Marie-Françoise Vecchierini1,2, Valérie Attali3,4, Jean-Marc Collet5, Marie-Pia d'Ortho6,7, Frederic Goutorbe8, Jean-Baptiste Kerbrat5,9, Damien Leger1,2, Florent Lavergne10, Christelle Monaca11, Pierre-Jean Monteyrol12, Eric Mullens13, Bernard Pigearias14, Francis Martin3, Hauria Khemliche15, Lionel Lerousseau16, Jean-Claude Meurice17. 1. AP-HP, Hôpital Hôtel Dieu, Centre du Sommeil et de la Vigilance, Paris, France. 2. Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 3. AP-HP Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service des Pathologies du Sommeil (Département "R3S"), Paris, France. 4. Sorbonne Université, INSERM, UMRS1158 Neurophysiologie Respiratoire Expérimentale et Clinique, Paris, France. 5. AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Stomatologie et Chirurgie Maxillo-Faciale, Paris, France. 6. Physiologie Clinique- Explorations Fonctionnelles et Centre du Sommeil, AP-HP, Hôpital Bichat-Claude Bernard, Paris, France. 7. Université de Paris, INSERM, UMR 1141 NeuroDiderot, Paris, France. 8. Centre Médecine du Sommeil, Centre Hospitalier de Béziers, Béziers, France. 9. Hôpital Charles Nicolle, Stomatologie et Chirurgie Maxillo-Faciale, Rouen, France. 10. ResMed Science Center, Saint-Priest Cedex, France. 11. Hôpital Roger Salengro, Neurophysiologie Clinique, Lille, France. 12. Polyclinique du Tondu, Oto-Rhino-Laryngologie, Bordeaux, France. 13. Fondation Bon Sauveur, Laboratoire du Sommeil, Albi, France. 14. Laboratoire du Sommeil, Nice, France. 15. Groupe Hospitalier Public Sud de l'Oise, Senlis, France. 16. Service de Pneumologie, Centre Hospitalier Antibes, Antibes. 17. Centre Hospitalier Universitaire, Pneumologie, Poitiers, France.
Abstract
STUDY OBJECTIVES: Mandibular advancement devices (MADs) are an alternative to continuous positive airway pressure for the management of obstructive sleep apnea (OSA). The ORthèse d'avanCée mAndibulaire dans le traitement en DEuxième intention du SAHOS sévère (ORCADES) study is investigating the long-term effectiveness of MAD therapy in patients with OSA who refused or were intolerant of continuous positive airway pressure. Five-year follow-up data are presented. METHODS: Data were available in 172 of 331 patients treated with a custom-made computer-aided design/computer-aided manufacturing biblock MAD (Narval CC; ResMed, Saint-Priest, France). The primary end point was treatment success (≥50% decrease in apnea-hypopnea index from baseline). RESULTS: Five-year treatment success rates were 52% overall and 25%, 52%, and 63%, respectively, in patients with mild, moderate, or severe OSA. This reflects a decline over time vs 3-6 months (79% overall) and 2 years (68%). Rates declined in all patient subgroups but to the greatest extent in patients with mild OSA. The slight worsening of respiratory parameters over time was not associated with any relevant changes in sleepiness and symptoms. Moderate or severe OSA at baseline, treatment success at 3-6 months, and no previous continuous positive airway pressure use were significant independent predictors of 5-year treatment success on multivariate analysis. No new safety signals emerged during long-term follow-up. The proportion of patients using their MAD for ≥4 h/night on ≥4 days/wk was 93.3%; 91.3% of patients reported device use of ≥6 h/night at 5 years. At 5-year follow-up, 96.5% of patients reported that they wanted to continue MAD therapy. CONCLUSIONS: Long-term MAD therapy remained effective after 5 years in >50% of patients, with good levels of patient satisfaction and adherence. CITATION: Vecchierini MF, Attali V, Collet JM, et al. Mandibular advancement device use in obstructive sleep apnea: ORCADES study 5-year follow-up data. J Clin Sleep Med. 2021;17(8):1695-1705.
STUDY OBJECTIVES: Mandibular advancement devices (MADs) are an alternative to continuous positive airway pressure for the management of obstructive sleep apnea (OSA). The ORthèse d'avanCée mAndibulaire dans le traitement en DEuxième intention du SAHOS sévère (ORCADES) study is investigating the long-term effectiveness of MAD therapy in patients with OSA who refused or were intolerant of continuous positive airway pressure. Five-year follow-up data are presented. METHODS: Data were available in 172 of 331 patients treated with a custom-made computer-aided design/computer-aided manufacturing biblock MAD (Narval CC; ResMed, Saint-Priest, France). The primary end point was treatment success (≥50% decrease in apnea-hypopnea index from baseline). RESULTS: Five-year treatment success rates were 52% overall and 25%, 52%, and 63%, respectively, in patients with mild, moderate, or severe OSA. This reflects a decline over time vs 3-6 months (79% overall) and 2 years (68%). Rates declined in all patient subgroups but to the greatest extent in patients with mild OSA. The slight worsening of respiratory parameters over time was not associated with any relevant changes in sleepiness and symptoms. Moderate or severe OSA at baseline, treatment success at 3-6 months, and no previous continuous positive airway pressure use were significant independent predictors of 5-year treatment success on multivariate analysis. No new safety signals emerged during long-term follow-up. The proportion of patients using their MAD for ≥4 h/night on ≥4 days/wk was 93.3%; 91.3% of patients reported device use of ≥6 h/night at 5 years. At 5-year follow-up, 96.5% of patients reported that they wanted to continue MAD therapy. CONCLUSIONS: Long-term MAD therapy remained effective after 5 years in >50% of patients, with good levels of patient satisfaction and adherence. CITATION: Vecchierini MF, Attali V, Collet JM, et al. Mandibular advancement device use in obstructive sleep apnea: ORCADES study 5-year follow-up data. J Clin Sleep Med. 2021;17(8):1695-1705.
Authors: Francesca Milano; Maria Celeste Billi; Francesca Marra; Giovanni Sorrenti; Antonio Gracco; Giulio A Bonetti Journal: Int Orthod Date: 2013-07-15
Authors: Fernanda Ribeiro de Almeida; Alan A Lowe; Satoru Tsuiki; Ryo Otsuka; Mary Wong; Sandra Fastlicht; Frank Ryan Journal: J Clin Sleep Med Date: 2005-04-15 Impact factor: 4.062
Authors: Olivier M Vanderveken; Marijke Dieltjens; Kristien Wouters; Wilfried A De Backer; Paul H Van de Heyning; Marc J Braem Journal: Thorax Date: 2012-09-19 Impact factor: 9.139
Authors: Winfried Randerath; Jan de Lange; Jan Hedner; Jean Pierre T F Ho; Marie Marklund; Sofia Schiza; Jörg Steier; Johan Verbraecken Journal: ERJ Open Res Date: 2022-06-27
Authors: Hasthi U Dissanayake; Juliana T Colpani; Kate Sutherland; Weiqiang Loke; Anna Mohammadieh; Yi-Hui Ou; Philip de Chazal; Peter A Cistulli; Chi-Hang Lee Journal: Clin Cardiol Date: 2021-11-17 Impact factor: 2.882